My Companies
Notification
Account
Log Out
Login
Board on 29 Oct approved preferential issue of up to 72 crore warrants convertible 1:1 into Re1 shares to promoters Hemal Mehta and Sachin Mehta at SEBI ICDR price, subject to regulatory and EGM approval. Context: extends recurring promoter warrant support at far larger scale.
Sudarshan Pharma Approves 9.5% MedTherapy Biotechnology Stake Acquisition
Sudarshan Pharma Promoters Pledge 66.5 Lakh Shares Each To Satin Finserv
Sudarshan Pharma Industries Promoters Pledge 1.32 Crore Shares To Satin Finserv
Sudarshan Pharma Converts USD1.5 Million FCCBs Into 48.1 Lakh Shares
Sudarshan Pharma Creates 3.25% Promoter Pledge To Secure Company Loan